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Circulation: Cardiovascular Interventions
ORIGINAL ARTICLE

Surgical Explantation of Transcatheter Aortic
Valve Bioprostheses
A Statewide Experience
Alexander A. Brescia , MD, MSc; G. Michael Deeb, MD; Stephane Leung Wai Sang, MD, MSc; Daizo Tanaka, MD;
P. Michael Grossman, MD; Devraj Sukul, MD, MSc; Chang He, MS; Patricia F. Theurer , MSN; Melissa Clark, MSN;
Francis L. Shannon, MD; Stanley J. Chetcuti, MD; Shinichi Fukuhara , MD; on behalf of the Michigan Society of Thoracic and
Cardiovascular Surgeons and the Blue Cross Blue Shield of Michigan Cardiovascular Consortium
BACKGROUND: Despite the rapid adoption of transcatheter aortic valve replacement (TAVR) since its initial approval in 2011,
the frequency and outcomes of surgical explantation of TAVR devices (TAVR-explant) is poorly understood.
METHODS: Patients undergoing TAVR-explant between January 2012 and June 2020 at 33 hospitals in Michigan were
identified in the Society of Thoracic Surgeons Database and linked to index TAVR data from the Transcatheter Valve Therapy
Registry through a statewide quality collaborative. The primary outcome was operative mortality. Indications for TAVRexplant, contraindications to redo TAVR, operative data, and outcomes were collected from Society of Thoracic Surgeons and
Transcatheter Valve Therapy databases. Baseline Society of Thoracic Surgeons Predicted Risk of Mortality was compared
between index TAVR and TAVR-explant.
RESULTS: Twenty-four surgeons at 12 hospitals performed TAVR-explants in 46 patients (median age, 73). The frequency of
TAVR-explant was 0.4%, and the number of explants increased annually. Median time to TAVR-explant was 139 days and
among known device types explanted, most were self-expanding valves (29/41, 71%). Common indications for TAVR-explant
were procedure-related failure (35%), paravalvular leak (28%), and need for other cardiac surgery (26%). Contraindications
to redo TAVR included need for other cardiac surgery (28%), unsuitable noncoronary anatomy (13%), coronary obstruction
(11%), and endocarditis (11%). Overall, 65% (30/46) of patients underwent concomitant procedures, including aortic
repair/replacement in 33% (n=15), mitral surgery in 22% (n=10), and coronary artery bypass grafting in 16% (n=7).
The median Society of Thoracic Surgeons Predicted Risk of Mortality was 4.2% at index TAVR and 9.3% at TAVR-explant
(P=0.001). Operative mortality was 20% (9/46) and 76% (35/46) of patients had in-hospital complications. Of patients alive
at discharge, 37% (17/37) were discharged home and overall 3-month survival was 73±14%.
CONCLUSIONS: TAVR-explant is rare but increasing, and its clinical impact is substantial. As the utilization of TAVR expands
into younger and lower-risk patients, providers should consider the potential for future TAVR-explant during selection of an
initial valve strategy.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: aortic valve ◼ aortic valve insufficiency ◼ aortic valve stenosis ◼ cardiac surgical procedures
◼ Michigan ◼ reoperation ◼ transcatheter aortic valve replacement

T

ranscatheter aortic valve replacement (TAVR) is
an established alternative to surgical aortic valve
replacement (SAVR) for patients with severe

symptomatic aortic stenosis, with a growing body of evidence demonstrating the short- and intermediate-term
durability of current TAVR devices.1,2 TAVR has rapidly
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WHAT IS KNOWN
• Repeat transcatheter aortic valve replacement
(TAVR) procedures for failed TAVR valves (redo
TAVR) have been performed in ≈0.3% to 0.4% of
patients.
• Patients with unsuitable anatomy or other contraindications to redo TAVR may undergo surgical explantation of TAVR bioprostheses in conjunction with
surgical aortic valve replacement (TAVR-explant).

WHAT THE STUDY ADDS
• By linking data from the Society of Thoracic Surgeons Adult Cardiac Surgery Database and
Transcatheter Valve Therapy Registry at Michigan
hospitals, this study provides the age of failed TAVR
valves and characterizes concurrent coronary and
valvular pathology at both the time of index TAVR
and TAVR-explant.
• The most common indications for TAVR-explant
procedures were procedure-related failure, paravalvular leak, and the need for other cardiac surgery.
• The most common contraindications to redo TAVR
in patients undergoing TAVR-explant were the need
for other cardiac surgery, unsuitable noncoronary
aortic root anatomy, coronary obstruction, and
endocarditis.

Nonstandard Abbreviations and Acronyms
ACSD
Adult Cardiac Surgery Database
CABG
coronary artery bypass grafting
MR
mitral regurgitation
SAVR
surgical aortic valve replacement
STS-PROM	Society of Thoracic Surgeons Predicted Risk of Mortality
TVT
transcatheter valve therapy
VIV
valve-in-valve

advanced from its original use in patients at prohibitive
surgical risk to those at low risk over the past decade.3,4
Since the inception of TAVR, an increasing number of
patients are requiring procedures for failed TAVR valves.
Initial reports of repeat TAVR for failed TAVR valves (eg,
redo TAVR) define an incidence of 0.33% to 0.40%1,2
and a large international series recently reported excellent short-term outcomes at 30 days and 1 year for
patients undergoing redo TAVR.2
However, these redo TAVRs were performed in select
patients with suitable anatomy, whereas the number of
TAVR valves requiring surgical explantation and SAVR
(TAVR-explant) due to unsuitable anatomy or other contraindications to redo TAVR was not reported. In addition,
long-term outcomes after redo TAVR are unknown and
the clinical impact of TAVR-explant to address TAVR valve

dysfunction has not been well described. An analysis of
the Society of Thoracic Surgeons (STS) Adult Cardiac
Surgery Database (ACSD) described TAVR-explant procedures as rare but morbid compared with similar patients
undergoing primary SAVR.5 However, these data only
extend to March 2015, and more contemporary singlecenter6 and STS ACSD7 analyses have shown that the
majority of TAVR-explants have occurred more recently.
A different national analysis of Medicare beneficiaries
found an incidence of 0.2% and comparable 30-day mortality to other series but ends in 2017 and lacks clinical
detail for concomitant surgical procedures, such as aortic repair.8 Furthermore, none of these national analyses
include procedural data from the index TAVR.5,7,8 Merging
clinical data from the index TAVR and subsequent TAVRexplant is essential to fully characterize the lifetime management of aortic stenosis in these patients.
Therefore, we linked data from the STS ACSD and
Transcatheter Valve Therapy (TVT) Registry through a
statewide quality collaborative to (1) define the frequency
of TAVR-explant in Michigan and (2) report the indications for and outcomes after TAVR-explant. We hypothesize that the frequency of TAVR-explantation will be
comparable to published rates and that older explanted
TAVR valves will be associated with more frequent and
complex concomitant procedures.

METHODS
Data Sources
Clinical data for surgical TAVR-explant procedures were collected from the STS ACSD through the Michigan Society of
Thoracic and Cardiovascular Surgeons Quality Collaborative,
developed in 2001 as a cardiac surgeon-led quality collaborative embedded in the Michigan Society of Thoracic and
Cardiovascular Surgeons including all 33 nonfederal hospitals
performing cardiac surgery in Michigan.
Clinical data for TAVR procedures were collected through
Michigan TAVR, a collaboration between the Michigan Society
of Thoracic and Cardiovascular Surgeons and Blue Cross
Blue Shield Cardiovascular Consortium. The Michigan TAVR
Coordinating Center receives quarterly data for Michigan from
the STS/American College of Cardiology TVT Registry.
This University of Michigan Institutional Review Board
deemed this study to be exempt from review (HUM00185363),
and the requirement for informed consent was waived. These
data cannot be made available due to data use restrictions.
Additional details pertaining to analytic methods are available
from the corresponding author upon reasonable request.

Patient Population
Patients undergoing SAVR and with a documented prior
TAVR procedure or documented TAVR valve explant between
January 1, 2012 and December 31, 2019, in Michigan were
identified from the STS ACSD (n=58). From these, 15 patients
who underwent redo TAVR and 1 undergoing heart transplantation after prior TAVR were excluded. The total number of
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TAVRs performed during the same period was collected from
the TVT Registry and used as the denominator for frequency.
An additional 4 patients undergoing TAVR-explant procedures
between January and June 2020 were included to total 46
patients with TAVR-explant in the final population (Figure 1).
STS dates of birth, sex, height, race/ethnicity, and date of
primary TAVR (if known) were used to develop an algorithm to
match STS records of TAVR-explant operations to TVT Registry
records for index TAVR procedures. In total 91% (42/46) of
patients were successfully linked. Reasons for unsuccessful
matching may include index TAVRs performed in a different
state or enrollment in a trial at the time of index TAVR. Date of
primary TAVR was available for 96% (44/46) of patients.

Surgical Explantation of TAVR Bioprostheses
Surgical technique for TAVR-explant procedures was determined according to surgeon preference. Circumferential device
neoendotheliazation was often present in older valve explants,
and careful dissection was required to avoid structural injuries
to the aorta, anterior mitral leaflet, and the membranous septum
(Figure 2A through 2D).
Explanted prostheses were either self-expanding (Medtronic,
Inc, Minneapolis, MN; n=29, 71%) or balloon-expandable
(Edwards Lifesciences, Irvine, CA; n=12, 29%) devices and
unknown in 5 patients. The surgical technique of early (<1 year)
and late (>1 year) explantation of both self-expanding and balloon-expandable devices has been described previously.6,9

Definitions and Outcomes
The primary outcome was operative mortality, defined as death
during the hospitalization or within 30 days after TAVR-explant.

Surgical TAVR Valve Explant in Michigan

A subgroup analysis included STS Predicted Risk of Mortality
(PROM) for isolated SAVR, which was reported at index TAVR
in 91% (42/46), TAVR-explant in 72% (33/46), and available
at both initial TAVR and TAVR-explant in 67% (31/46).
Secondary outcomes included time to TAVR-explant, index
TAVR echocardiographic data, need for concomitant procedures
during TAVR-explant, in-hospital complications, discharge location, 30-day readmission, and all-cause mortality. Individual inhospital complications included permanent stroke, reoperation
for bleeding, new renal failure, postoperative atrial fibrillation,
and new permanent pacemaker placement. Echocardiographic
data before and after index TAVR was collected from the TVT
Registry. Late TAVR-explant occurred >1 year after the initial
TAVR procedure and early explant occurred <1 year from initial
TAVR, as defined previously.2,6
Indications for TAVR-explant were collected from the STS
ACSD versions 2.73, 2.81, and 2.9 and could include >1 per
patient (Appendix in the Data Supplement). Patients with a
need for other cardiac surgery indication also met ≥1 valverelated indications for TAVR-explant. Indications failed repair
and sizing/position issue as defined in the STS ACSD were
combined and categorized as procedure-related failure to
encompass devices that failed either during the index TAVR or
afterward for reasons directly related to the procedure. Patient
TVT and STS data were used by the authors to determine contraindications to redo TAVR for 74% (34/46) of patients, which
also sometimes included >1 per patient.

Statistical Analysis
Normally distributed continuous variables are expressed as
mean±SD, and non-normally distributed variables are expressed
as median (interquartile range). Bivariate comparisons utilized

Figure 1. Flow diagram of patient population.
SAVR indicates surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; and TVT, transcatheter valve therapy.
Circ Cardiovasc Interv. 2021;14:e009927. DOI: 10.1161/CIRCINTERVENTIONS.120.009927
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Figure 2. Intraoperative images of a 3-y-old transcatheter aortic valve replacement (TAVR) self-expanding valve explant.
A, Denuded aortic intima due to severe endothelialization. B, Severely adherent stent cage to the membranous septum. C, Severely adherent
stent cage to the anterior mitral leaflet and chordae tendinae. D, Disintegrated right coronary sinus after the TAVR valve removal.

paired, 2-tailed t tests for normally distributed continuous variables, Wilcoxon rank-sum tests for non-normally distributed continuous variables, and Fisher exact tests for categorical variables.
A spaghetti plot displayed STS-PROM at initial TAVR and
TAVR-explant and medians were compared with the Wilcoxon
rank-sum test. Time-to-event survival analyses were performed
using the log-rank test and Kaplan-Meier estimates with corresponding 95% CIs. Two time-to-event analyses were performed: cumulative frequency of TAVR-explant from date of
index TAVR with TAVR-explant treated as a failure event and
cumulative survival after TAVR-explant.
P<0.05 (2-tailed) were considered statistically significant.
Analyses were conducted using Stata 16.0 (StataCorp LLC,
College Station, TX).

RESULTS
TAVR-Explant Frequency
The frequency of TAVR-explant between 2012 and
2019 was 0.43% (42/9756), and the number of TAVRexplants increased annually from 1 in 2013 to 17 in 2019
(Figure 3), whereas the number of TAVR procedures also
increased from 141 in 2012 to 2404 in 2019 (Figure I
in the Data Supplement). Among 157 cardiac surgeons
at 33 hospitals in Michigan, 15% (n=24) of surgeons at
36% (12/42) of hospitals performed ≥1 TAVR-explant
(median, 1; range, 1–12 per surgeon).

Patient Characteristics
Mean age was 73±8 years, and 33% (n=15) were female
(Table 1). At the time of TAVR-explant, 50% (n=23) had
chronic lung disease, 43% (n=20) a history of cerebrovascular disease, 15% (n=7) prior stroke, and 28%
(n=13) a permanent pacemaker. Mean left ventricular
ejection fraction was 50±14%, 14% (n=6) of patients
had undergone a prior coronary artery bypass grafting
(CABG), 11% (n=5) had a porcelain aorta, and 7% (n=3)
had a history of mediastinal radiation.
Eighty-seven percent (34/39) of patients presented
with New York Heart Association functional class III/IV
heart failure. Among those with available STS-PROM
(n=33), 58% (n=19) were at high surgical risk (>8%).
The overall median STS-PROM at TAVR-explant was
8.9% (5.4–18.2), which was higher for late versus early
explants (14% [7.3–33.6]) versus 6.5% [3.8–17.3];
P=0.13; Table 1); however, this did not reach statistical
significance.

Index TAVR Data
Data from the index TAVR were available for 91%
(42/46) patients (Table I in the Data Supplement). Most
presented with New York Heart Association III/IV (n=31)
symptoms and the 2 most common indications for TAVR
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Figure 3. Number of transcatheter
aortic valve replacement (TAVR)–
explants per year.
Each year is stratified by patient risk at
index TAVR (low, intermediate, high, or
prohibitive).

were primary aortic stenosis (n=26, 63%) and failed bioprosthetic valve requiring valve-in-valve (VIV) procedures
(n=14, 33%). Thirty-three percent of patients (n=14)
were classified as intermediate risk for surgery at time of
TAVR, 48% (n=20) were high risk, and 19% (n=8) were
prohibitive/extreme risk.
Table 1.

Between 2012 and 2019 in Michigan, 40.3%
(3935/9756) of TAVR devices implanted were selfexpanding, whereas 59.2% (5771/9756) were balloon-expandable. Among eventual TAVR-explants, 71%
(n=29) had a self-expanding device implanted at the
index TAVR, whereas 29% (n=12) patients received a

Patient Characteristics at Time of TAVR-Explant

Characteristic

Overall (n=46)

Early explant
(<1 y, n=28)

Late explant
(>1 y, n=16)

P value

Age, y

73±8

75±8

71±8

0.15

Female sex

15 (33)

6 (21)

8 (50)

0.09

Hypertension

41 (89)

23 (82)

16 (100)

0.14

Diabetes

16 (35)

8 (29)

7 (44)

0.34

Dialysis

6 (13)

4 (14)

2 (13)

1.00

Chronic lung disease

23 (50)

12 (43)

9 (56)

0.53

Cerebrovascular disease

20 (43)

13 (46)

6 (38)

0.75

Prior stroke

7 (15)

5 (18)

2 (13)

1.00

Permanent pacemaker

13 (28)

9 (32)

4 (25)

0.74

Peripheral vascular disease

9 (20)

6 (21)

3 (19)

1.00

Previous myocardial infarction

17 (37)

10 (36)

7 (44)

0.75

30.9±8.0

28.3±8.1

34.1±6.3

0.018

Left ventricular ejection fraction

50±14%

51±15%

49±13%

0.69

Porcelain aorta

5 (11)

2 (7)

3 (19)

0.34

Body mass index, kg/m

2

History of mediastinal radiation

3 (7)

0

3 (19)

0.042

Prior CABG

6 (14)

3 (12)

3 (19)

0.66

NYHA class III/IV (n=39)

34 (87)

19 (83)

13 (93)

0.63

STS predicted risk of mortality, median (interquartile range) [n=33]

8.9% (5.4–18.2)

6.5% (3.8–17.3)

14.0%
(7.3–33.6)

0.13

Low (<4%)

6 (18)

5 (26)

1 (8)

0.44

Intermediate (4–8%)

8 (24)

5 (26)

3 (23)

0.44

High (>8%)

19 (58)

9 (47)

9 (69)

0.44

Values are expressed as n (%), mean±SD, or median (interquartile range). CABG indicates coronary artery bypass grafting;
NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; and TAVR, transcatheter aortic valve replacement.
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balloon-expandable device. Due to intraprocedural positioning errors, a second self-expanding TAVR device was
implanted in 3 patients during the index TAVR procedure.
On preTAVR echocardiogram, 5% (n=2) patients had
mitral stenosis, 32% (n=13) had moderate or worse
mitral regurgitation (MR), and 23% (n=9) had moderate or worse tricuspid regurgitation. Post-TAVR echocardiogram showed mild paravalvular leak in 21% (n=8) of
patients and moderate paravalvular leak in 15% (n=5),
whereas the rest had none.

Indications for TAVR-Explant and Operative
Data
The most common indications for TAVR-explant
included procedure-related failure (35%), paravalvular leak (28%), need for other cardiac surgery (26%),
and endocarditis (13%; Figure 4A and Figures II and
III in the Data Supplement). Contraindications to redo
TAVR included need for other cardiac surgery (28%),
unsuitable noncoronary anatomy (13%), risk of coronary obstruction (11%), endocarditis (11%), and were
unknown in 26% (n=12) of patients (Figure 4B).
Unsuitable noncoronary anatomy included prior VIV
procedures in 4 patients and an oversized annulus
perimeter in 2 patients, precluding redo TAVR. In the
subgroup analysis of 31 patients with complete STSPROM scores, the median STS-PROM was significantly
higher at TAVR-explant (9.3% [5.6–18.8]) compared
with index TAVR (4.2% [2.5–8.9]; P=0.001, Figure 5).
Among patients with known procedure dates (n=44),
the median time between TAVR and TAVR-explant was
139 (3–611) days (Figure 6), including 11 patients
(25%) who underwent emergent/urgent conversion
to TAVR-explant and SAVR on the same day as the
index TAVR. All other patients (33/44, 75%) underwent
TAVR-explant during a subsequent hospitalization after
index TAVR. Sixty-one percent of patients (n=28/46)
had undergone at least one previous sternotomy, more
frequently among late versus early explants (81%
[13/16] versus 46% [13/28], P=0.030). A higher
proportion of late explants underwent elective procedures, whereas more early explants were emergent
(Table 2). Median cardiopulmonary bypass and crossclamp times were 165 (131–235) and 121 (95–174)
minutes, respectively. Seventy-eight percent of patients
(n=36) received a stented bioprosthesis, whereas 4%
(n=2) received a stentless bioprosthesis and 7% (n=3)
a mechanical valve.
Sixty-five percent of patients (n=30) underwent
concomitant procedures during TAVR-explant, including 33% (15/46) undergoing aortic repair/replacement, 22% (10/46) mitral repair/replacement, and
16% (7/46) CABG. Among the 15 patients who underwent a concomitant aortic procedure (n=11 explants of
self-expanding devices and n=4 balloon-expandable),

Surgical TAVR Valve Explant in Michigan

12 underwent ascending repair/replacement (n=9
self-expanding and n=3 balloon-expandable), 7 aortic
root repair/replacement (n=6 self-expanding and n=1
balloon-expandable), and 3 aortic arch procedures. A
higher proportion of late versus early explants underwent concomitant procedures (88% versus 50%,
P=0.021; Table 2).
Among patients undergoing nonaortic concomitant
procedures with TVT index TAVR data available, 55%
(5/9) who underwent concomitant mitral surgery had
moderate or worse MR at the time of TAVR, 60% (3/5)
undergoing tricuspid repair had moderate or worse tricuspid regurgitation, and 60% (3/5) undergoing CABG
had significant coronary disease.

Postexplant Outcomes
Mortality in the hospital or within 30 days was 20%
(9/46), including 45% (5/11) among patients emergently/urgently converted on the same day as index
TAVR. Median postoperative length of stay among those
discharged alive was 11 (9–17) days. In total 76%
(35/46) of patients had at least one postoperative inhospital complication, including 37% (17/46) with new
postoperative atrial fibrillation, 23% (9/40) new renal
failure, 11% (5/46) reoperation for bleeding, 6% (2/33)
new permanent pacemaker placement, and 4% (2/46)
permanent stroke. Among those alive at discharge, 37%
(17/37) were discharged to home and 30-day readmission was 27% (10/37). Postoperative outcomes did
not statistically differ between early versus late TAVRexplants (Table 3). TAVR-explants who had undergone
prior VIV procedures for failed bioprosthetics had a 0%
(0/14) operative mortality, 64% (9/14) had at least one
in-hospital complication, 71% (10/14) were discharged
home, and 30-day readmission was 14% (2/14).
All-cause mortality was 33% (15/46) at median 14.1
(2.8–40.8) months follow-up after index TAVR and 1.8
(0.7–6.5) months after TAVR-explant. Estimated survival
after TAVR-explant was 73±14% at 3 months, 68±15%
at 6 months, and 56±20% at 12 months (Figure IV in the
Data Supplement).

DISCUSSION
This is the first study using multicenter registry data to
comprehensively describe patients undergoing TAVRexplant by linking TVT Registry TAVR procedural and STS
ACSD surgical TAVR-explant data. Collectively, these
data indicate that TAVR-explants are rare but increasing
in frequency, often require concomitant cardiac surgery,
and confer significant operative mortality and morbidity.
Prior analyses have described redo TAVR with an
incidence of 0.4%1 and 0.33%,2 with a recent international registry analysis reporting an excellent 5.4%
30-day mortality among patients with early (<1 year)
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Figure 4. Procedure indications and
contraindications.
A, Indications for transcatheter aortic
valve replacement (TAVR)–explant. B,
Contraindications to redo TAVR. TAVRexplant indications were available for
all patients, while contraindications to
redo TAVR were determined for 34/46
(74%) patients. Some had more than one
indication or contraindication. Patients with
a need for other cardiac surgery also met ≥1
valve-related indications for TAVR-explant.

valve dysfunction and 1.4% among those with late (>1
year) dysfunction prompting redo TAVR.2 However, these
analyses are restricted to transcatheter registry data and
do not address the population of patients with TAVR with
contraindications to redo TAVR. The 0.4% frequency in
this study suggests that TAVR-explant may be at least
as common as redo TAVR. Tang et al10 established an
interesting model which estimated that redo TAVR after
Sapien 3 TAVR would be unfeasible in 21.4% of cases.
However, the model focuses specifically on the risk of
coronary obstruction based on leaflet or stent frame
interaction with coronary arteries. The overall feasibility

of redo TAVR is likely lower than predicted through this
model since the analysis could not consider progression of thrombus, leaflet thickening, and calcification of
the native/prosthetic valve or the aortic root over time,
potential device constraint of the second TAVR valve,
and progression of other synchronous/de novo cardiac
pathologies. These factors cannot be appreciated on
intraoperative angiogram at the time of index TAVR.6,11
In addition, the requirement for concomitant procedures
common in this, and prior7 studies presents another contraindication to redo TAVR. Future analyses should evaluate both redo TAVR and TAVR-explant within the same
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Figure 5. Society of Thoracic Surgeons (STS) Predicted
Risk of Mortality (PROM) at index transcatheter aortic valve
replacement (TAVR) and TAVR-explant.
An STS-PROM was available at both times in 67% (31/46) of
patients.

dataset to fully characterize the incidence, indications,
and outcomes of transcatheter or surgical reintervention
for failed TAVR valves.
Other studies have described TAVR-explants using
surgical databases5,7 or Medicare data.8 Interestingly, in
an STS ACSD analysis between 2011 and 2015,5 only
7% of patients underwent root replacement, 2.4% mitral
replacement, and 5.7% CABG concomitant to TAVRexplant, compared with 33% who underwent concomitant aortic procedures, 22% mitral, and 16% CABG in
this series. These drastic differences may indicate that
TAVR-explant procedures became more complicated
after 2015, this series may include a higher proportion of late explants, or that regional differences exist
between our state and national data. Additionally, 33%
of patients in the current study underwent TAV-in-SAV
VIV procedures before subsequently requiring TAVRexplant, whereas the STS ACSD database analysis does
not include data from the index TAVR and the number of
VIV procedures is unknown.5
A more updated STS ACSD analysis including TAVRexplants between 2011 and 2018 found a 19.4%
30-day mortality among 782 patients, higher among
patients undergoing concomitant procedures (23.8%)
versus isolated SAVR (14.8%; P=0.002).7 In contrast
to the 2011 to 2015 study with rare concomitant procedures,5 the authors reported ascending aortic or
root replacement in 25.6%, mitral surgery in 21.1%,
and CABG in 15.6%, which were comparable to the
current study. Notably, these analyses were unable to
define TAVR-explant frequency due to data limitations,
although Jawitz et al5 estimated a 0.3% TAVR-explant
incidence. Although one prior study has analyzed data
from index TAVR and TAVR-explant within the same
dataset and reported a 1.0% TAVR-explant frequency,
this was a single-center study with only 17 patients.6

Surgical TAVR Valve Explant in Michigan

Figure 6. Time to valve failure from index transcatheter aortic
valve replacement (TAVR) to TAVR-explant.
Two patients (2/46, 4%) were excluded due to an unknown date of
index TAVR.

Because the majority of patients in this and prior studies were high-risk when faced with TAVR-explant,
we hypothesize that the incidence of TAVR-explant
reported here and elsewhere likely underestimates the
incidence of failed TAVR valves since some patients
were likely not offered redo TAVR or TAVR-explant due
to their extremely high-risk status.
Another recent analysis of TAVR-explant procedures in Medicare beneficiaries from 2012 to 2017
found an incidence of 0.2%.8 The authors reported
8.4% underwent concomitant CABG and 4.4% other
valve procedures and a similarly high mortality at
13.2% and 17.6% at 30 and 90 days, respectively.8
However, these data are limited to Medicare beneficiaries and most importantly do not fully capture concomitant procedures at TAVR-explant, such as aortic
repair. Given that the rates of concomitant procedures
and specifically aortic repair/replacement were 65%
and 33% in this study and 55.9% and 25.6% in the
nationally-representative STS ACSD analysis,7 capturing these data are important to inform lifetime management of severe aortic stenosis patients and we
question whether these patients may have received
incomplete therapy at their index TAVR.
Prior multicenter analyses have notably not
included TAVR procedural and echocardiographic
data, which are essential to understanding why TAVR
valves fail and differentiating between concomitant
pathologies, such as MR, tricuspid regurgitation, or
coronary disease being present at the time of TAVR
versus developing in the interval between TAVR and
TAVR-explant. In this study, 55% (5/9) of patients who
underwent concomitant mitral surgery had moderate
or worse MR at the initial TAVR. As prior studies have
shown, both mitral stenosis12 and MR13 left untreated
at index TAVR are associated with higher mortality.
Furthermore, the majority of patients who underwent
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Table 2.

TAVR-Explant Operative Data

Characteristic

Overall (n=46)

Early explant (<1
y, n=28)

Late explant (>1
y, n=16)

P value

Redo sternotomy

28 (61)

13 (46)

13 (81)

0.030

Elective

20 (43)

9 (32)

10 (63)

0.025

Urgent

18 (39)

11 (39)

6 (38)

0.025

Emergent/salvage

8 (17)

8 (29)

0

0.025

Cardiopulmonary bypass time, min

165 (131–235)

159 (131–234)

193 (131–253)

0.62

Cross-clamp time, min

121 (95–174)

120 (85–155)

153 (105–184)

0.20

Circulatory arrest

5 (11)

5 (18)

0

0.14

Balloon-expandable

12 (26)

9 (32)

3 (19)

0.19

Self-expanding

29 (63)

16 (57)

13 (81)

0.19

Unknown

5 (11)

3 (11)

0

0.19

Explanted device size, mm

29 (26–34)*

29 (26–34)

27.5 (23–31)

0.17

Explanted device age, d

139 (3–611)*

37 (0–109)

809 (486–1320)

<0.001

Stented bioprosthesis

36 (78)

21 (75)

13 (81)

0.49

Stentless bioprosthesis

2 (4)

2 (7)

0

0.49

Mechanical valve

3 (7)

1 (4)

2 (13)

0.49

Other

5 (11)

4 (14)

1 (6)

0.49

Implant device size, mm

25 (23–27)

25 (23–27)

23 (23–25)

0.11

Concomitant procedures

30 (65)

14 (50)

14 (88)

0.021

Annular enlargement

5 (11)

1 (4)

4 (25)

0.06

Mitral

10 (22)

3 (11)

6 (38)

0.06

Coronary artery bypass grafting

7 (16)

2 (7)

3 (19)

0.34

Tricuspid

6 (13)

4 (15)

2 (13)

1.00

Aortic procedure

15 (33)

7 (26)

8 (50)

0.19

  Root repair/replacement

7 (15)

2 (7)

5 (31)

0.08

  Ascending repair/endarterectomy

12 (26)

7 (25)

5 (31)

0.73

  Arch

3 (7)

3 (11)

0

0.29

Operative status

Explanted device type

Implanted prosthesis

1 (2)

1 (4)

0

1.00

Multiple concomitant procedures

Ventricular septal defect repair

8 (17)

2 (7)

5 (31)

0.08

Intra-aortic balloon pump

3 (7)

2 (7)

1 (6)

1.00

ECMO

4 (9)

3 (11)

1 (6)

1.00

Values are expressed as n (%) or median (interquartile range). ECMO indicates extracorporeal membrane oxygenation; and TAVR,
transcatheter aortic valve replacement.
*n=44 patients.

concomitant tricuspid repair and CABG had moderate
or worse tricuspid regurgitation or significant coronary
disease, respectively, at the time of index TAVR. Given
the median number of TAVR-explants per surgeon was
1, we expect an associated learning curve (particularly with older TAVR valves), which may contribute to
the high reported mortality and morbidity rates. Additionally, the need for other cardiac surgery at time of
TAVR-explant was present in >25% of patients and
may result from incomplete therapy of synchronous
cardiac pathology at the initial intervention.
These data raise a concern for the appropriateness
of TAVR as a first valve strategy in younger, healthier

patients who inevitably outlive the lifespan of their TAVR
valves. With recent favorable outcomes after TAVR in
low-risk patients3,4 and the subsequent Centers for
Medicare and Medicaid National Coverage Decision
which may double the number of hospitals eligible to
perform TAVR,14 the number of TAVR procedures performed in low-risk patients is expected to increase
substantially. Although a 0.4% TAVR-explant frequency
reinforces similarly low incidences reported with TAVRexplant in Medicare (0.2%)8 and redo TAVR data
(0.33%),2 this study importantly does not include any
patients undergoing TAVR-explant who were deemed
low-risk at their index TAVR.
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Table 3.

Postoperative Outcomes by Timing of TAVR-Explant

Characteristic

Overall (n=46)

Early (<1 y, n=28)

Late (>1 y, n=16)

P value

Operative mortality

9 (20)

6 (21)

3 (19)

1.00

ICU length of stay, h

113 (47–209)

112 (52–172)

146 (45–229)

0.57

In-hospital complication, %

35 (76)

20 (71)

13 (81)

0.72

2 (4)

2 (7)

0

0.53

Permanent stroke
Reoperation for bleeding

5 (11)

2 (7)

3 (19)

0.34

New renal failure*

9 (23)

4 (17)

4 (29)

0.43

Atrial fibrillation

17 (37)

11 (39)

5 (31)

0.75

New pacemaker†
Postoperative length of stay, d‡

2 (6)

0

2 (17)

0.14

11 (9–17)

10 (8–16)

12 (9–25)

0.23

Discharge location‡
Home

17 (37)

9 (39)

8 (67)

0.16

Extended/transitional care/rehab

19 (41)

14 (61)

4 (33)

0.16

Nursing home
30-day readmission‡

1 (2)

0

0

0.16

10 (27)

5 (23)

5 (42)

0.44

All-cause mortality

15 (33)

9 (32)

6 (38)

0.75

Follow-up after TAVR-explant, mo

1.8 (0.7–6.5)

1.6 (0.4–11.0)

2.0 (0.9–5.3)

0.97

Values are expressed as n (%) or median (interquartile range). ICU indicates intensive care unit; and TAVR, transcatheter aortic valve
replacement.
*n=40 without end-stage renal disease preoperatively.
†n=33 without a permanent pacemaker preoperatively.
‡n=37 patients alive at discharge.

Limitations
This study has several limitations. First, it is descriptive, with a relatively small sample size. However, this is
the only registry analysis providing linked STS and TVT
data, which provides unique insights into TAVR-explants
which cannot be obtained from STS ACSD or Medicare data alone. Second, insights into operative technique are limited in this database study. However, we
include important procedural data from both the TAVR
and TAVR-explant procedures and have previously published on TAVR-explant technique in significant detail.6,9
Third, the granularity of TAVR-explant indications is limited to data reported in the STS ACSD, which is a limitation of registry studies. Fourth, follow-up is short for
recent TAVR procedures, which comprise the majority
of TAVRs performed. As a result, future analyses may
show that TAVR-explants occur at later times than represented in these data.

Conclusions
TAVR-explant is a rare, but clinically significant procedure required for some patients with failed TAVR valves.
These procedures carry a higher risk of surgical mortality
than at the time of index TAVR and two-thirds of patients
in this series required concomitant cardiac surgical procedures at the time of TAVR-explant. As the widespread
adoption of TAVR continues and the number of younger,
lower-risk patients become TAVR candidates, providers should consider these data in the context of lifetime

management to determine the best initial valve strategy
for severe aortic stenosis patients.
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